title: [Management of hypercortisolism].
abstract: OBJECTIVE
  Cushing's syndrome is a rare but frequently considered disease. Its diagnosis can lead to some difficulties, including confirming the effective endogenous hypercortisolism and determining its cause. The severity of this disease, the diversity of its complications and the multiple therapeutic options make its management challenging. The aim of this review is to present the most recent data about management of Cushing's syndrome, especially diagnostic approaches and therapeutic options. Our references were obtained by screening MEDLINE database from 1996 to 2006. We also included some anterior reviews and consensus statements.
  
  
  RESULTS
  We retained the following points: midnight salivary cortisol is a useful tool in the diagnosis of Cushing's syndrome; the desmopressin test can help to distinguish between Cushing's syndrome and "pseudoCushing's" due to alcohol consumption or psychiatric disorders; cavernous sinus and inferior petrosal sinus sampling is indicated in the evaluation of ACTH-dependent Cushing's syndromes when pituitary imaging is normal or equivocal or when dynamic tests are contradictory; multislice computed-tomography of the chest and the abdomen and somatostatin analogue scintigraphy, eventually combined, are the best imaging procedures in occult ectopic ACTH syndromes; patients with Cushing's disease should be referred to a neurosurgeon experienced in corticotroph adenomas surgery; metabolic consequences of Cushing's syndrome, such as cardiovascular risk factors and osteoporosis need an aggressive treatment.
  
  
  CONCLUSIONS
  The incidence of Cushing's syndrome is only 1/100000 per year. However, hypercortisolism is diagnosed by systematic evaluation in 2 to 5% of patients with poorly controlled type 2 diabetes and adrenal incidentalomas. Endocrinological management of the disease improves metabolic disorders in these patients. If these results are confirmed, screening for Cushing's syndrome should be systematically performed in these populations.
authors.affiliation: Service d'endocrinologie, hôpital Ambroise-Paré, Assistance publique-Hôpitaux de Paris, 9, avenue Charles-de-Gaulle, 92100 Boulogne, France.
authors.forename: C
authors.initials: C
authors.lastname: Rosales
authors.forename: H
authors.initials: H
authors.lastname: Fierrard
authors.forename: X
authors.initials: X
authors.lastname: Bertagna
authors.forename: M-L
authors.initials: ML
authors.lastname: Raffin-Sanson
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003480:Cushing Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D003663:Decision Trees; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007016:Hypophysectomy; D007654:Ketoconazole / Q000627:therapeutic use; D008939:Mitotane / Q000627:therapeutic use; D010902:Pituitary Gland / Q000528:radiation effects
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004791:Enzyme Inhibitors; D008939:Mitotane; D007654:Ketoconazole